摘要
宫颈癌是女性最常见的恶性肿瘤之一,复发或转移性宫颈癌5年生存率仅为17%,临床治疗十分棘手;程序性死亡受体1(programmed death-1,PD-1)单抗已用于复发或转移性宫颈癌一线治疗。但PD-1单抗单药治疗存在客观反应率低和易耐药等瓶颈,限制了临床应用。近年来,过继性细胞免疫治疗改变了癌症免疫治疗的格局。过继性细胞免疫治疗主要通过向体内回输具有抗肿瘤活性的免疫细胞,从而达到抗肿瘤的目的。目前过继性细胞免疫治疗主要有3种类型:肿瘤浸润性淋巴细胞、T细胞受体修饰T细胞和嵌合抗原受体T细胞。相关研究表明过继性细胞免疫治疗对改善晚期宫颈癌患者生存及预后具有重要价值。综述过继性细胞免疫治疗的原理、生物学特征、在宫颈癌治疗中的应用及局限性,以期通过优化其生产技术并与其他肿瘤治疗方式联合治疗,为提高宫颈癌免疫治疗疗效提供新的思路。
Cervical cancer is one of the most common malignant tumors among women.The 5-year survival rate of recurrent or metastatic cervical cancer is only 17%and the clinical treatment is very tricky.Programmed death-1(PD-1)monoclonal antibody has been used as a first-line treatment for recurrent or metastatic cervical cancer.However,the bottlenecks for PD-1 monoclonal antibody monotherapy are relatively lower objective response rate and higher drug resistance rate,which limits its clinical application.Recently,adoptive cell immunotherapy altered the landscape of cancer immunotherapy,which achieved antitumor effects by infusing antitumor cells back to the body.Currently,there are mainly three types of adoptive cell immunotherapy including tumor-infiltrating lymphocyte,T-cell receptor-engineered T cells and chimeric antigen receptor T-cell.Relative studies have demonstrated the significant value of adoptive cell immunotherapy on improvement of survival and prognosis for patients with advanced cervical cancer.The principles,biological characteristics,applications and limitations for adoptive cell immunotherapy are summarized in the review.Optimizing the productive technology and being combined with other oncological treatment may supply new ideas for cervical cancer immunotherapy.
作者
张蓝月
申复进
ZHANG Lan-yue;SHEN Fu-jin(Department of Obstetrics and Gynecology,Renmin Hospital of Wuhan University,Wuhan 430060,China)
出处
《国际妇产科学杂志》
CAS
2024年第3期253-257,共5页
Journal of International Obstetrics and Gynecology
基金
湖北省自然科学基金一般面上项目(2021CFB430)。
